Trial Profile
Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Dulaglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 7
- Sponsors Novo Nordisk
- 26 Jun 2023 Results assessing proportion of participants treated with once-weekly semaglutide, or a comparator, achieving a metabolic composite target endpoint from SUSTAIN trials (1 - 5 and 7 - 10) and SUSTAIN China presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2023 Results of an analysis assessing efficacy and safety of Tirzepatide, dulaglutide and Semaglutide (common comparator) using adjusted indirect comparisons using results data from two clinical trials: SURPASS-1 and SUSTAIN-7 presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 08 Aug 2022 Results published in the Diabetes Therapy